Aerospace company tapped for mission for new spacewalk, moonwalk system

in the works

NASA has issued another grant to Collins Aerospace to design the future of spacewalks and moonwalks. Image via NASA

Charlotte, North Carolina-based Collins Aerospace has been selected by NASA to develop a spacewalking system for the astronauts aboard the International Space Station.

The award, which is the second under NASA’s Exploration EVA Services contract, has a base value of $97.2 million, per a Dec. 8 news release from NASA. The company has until January 2024 "to complete a critical design review and demonstrate use of the suit on Earth in a simulated space environment," according to NASA, which will then decide the option to extend the contract for testing to be conducted by April 2026.

NASA’s Johnson Space Center in Houston manages the spacesuit contract. Collins Aerospace has had a presence in Houston for 40 years, and recently cut the ribbon on a $30 million facility near the JSC.

“We look forward to obtaining another much-needed service under our contract,” says Lara Kearney, manager of the Extravehicular Activity and Human Surface Mobility Program at JSC, in the release. “By working with industry, NASA is able to continue its over 22-year legacy of maintaining a presence in low-Earth orbit.”

The current system was designed decades ago and has been used during previous space shuttle and space station missions. Collins Aerospace will work with Houston-based Axiom Space on this project, which was initially announced this summer.

"Both vendors will continue to compete for future task orders which include recurring services for station spacewalks and moonwalks beyond Artemis III," the news release reads.

Axiom Space will outfit our astronauts. Photo courtesy of NASA

Houston tech company lands exclusive spacesuit deal for NASA's mission to moon

suit up

When astronauts make a historic return to the surface of the moon, presumably 2025 or 2026, they’ll don Houston-crafted, life-protecting suits.

Houston-based Axiom Space has landed the rights to create spacesuits and supporting systems for NASA’s Artemis III mission, which will see humans back on our satellite for the first time since the legendary Apollo missions more than 50 years ago.

This award is the first for a competitive spacesuits contract, NASA notes in a press release. NASA tapped Axiom Space for a task order boasting a base value of $228.5 million. As previously reported, Axiom Space was one of two companies NASA pegged for spacesuit and supporting system development.

These new suits are pivotal, as plans for NASA’s Artemis lunar program call for not just lunar orbit, but trips to the lunar south pole and even a crewed outpost on the moon.

Axiom Space will be responsible for the design, development, qualification, certification, and production of its spacesuits and support equipment. Spacesuits will be tested for moonwalks and spacewalks.

This spacesuit contract, which will advance spacewalking capabilities in low-Earth orbit and on the Moon, is managed by the Extravehicular Activity and Human Surface Mobility Program (EHP) at Johnson Space Center.

“NASA is proud to partner with commercial industry on this historic mission that will kickstart the United States building a lasting presence on the surface of the Moon,” said Lara Kearney, manager of NASA’s Extravehicular Activity and Human Surface Mobility program. “What we learn on Artemis III and future missions on and around the Moon will pave the way for missions to Mars. Spacesuits enable us to literally take that next step.”

The first lunar mission since 1972, Artemis will be historic in myriad ways, none of least for seeing the first woman and the first person of color on the moon, as well as a testing ground for eventual Mars missions.

Artemis I is set to launch on September 19, barring any delays.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings